GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » Cash Flow from Investing

Aprea Therapeutics (Aprea Therapeutics) Cash Flow from Investing : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Aprea Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Aprea Therapeutics gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Aprea Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Aprea Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprea Therapeutics Cash Flow from Investing Chart

Aprea Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -0.03 -0.03 - - -0.09

Aprea Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aprea Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Aprea Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Aprea Therapeutics's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aprea Therapeutics  (NAS:APRE) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Aprea Therapeutics's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Aprea Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Aprea Therapeutics's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Aprea Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Aprea Therapeutics's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Aprea Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Aprea Therapeutics's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Aprea Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Aprea Therapeutics's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Aprea Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Aprea Therapeutics's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Aprea Therapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Aprea Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Aprea Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Aprea Therapeutics's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Aprea Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Aprea Therapeutics's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Aprea Therapeutics paid $0.00 Mil for other investing activities.


Aprea Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprea Therapeutics (Aprea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Executives
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
John P. Hamill officer: SrVP/CFO/Prin. Fin &Acctg. Off 4092 NEW HOPE ROAD, FURLONG PA 18925
Michael Grissinger director C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Marc Duey director 27 STRATHMORE ROAD, NATICK MA 01760
Oren Gilad officer: President, CEO 535 BOYLSTON STREET, BOSTON MA 02116
Rifat Pamukcu director 535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade director, officer: President & CEO MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar officer: SVP, Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel officer: Chief Business Officer 535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen officer: SVP, Chief Scientific Officer 535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
5am Ventures Iv, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Aprea Therapeutics (Aprea Therapeutics) Headlines

From GuruFocus

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

By sperokesalga sperokesalga 06-14-2023